DiscoverLung Cancer ConsideredSeminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC
Seminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC

Seminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC

Update: 2024-02-29
Share

Description

Today’s episode of Lung Cancer Considered is part of our special series on seminal trials in thoracic oncology, focusing on the phase I study of the PD-1 inhibitor nivolumab. Hosts Dr. Narjust Florez and Dr. Stephen Liu discuss that study with guest Dr. Julie Brahmer from Johns Hopkins University. This podcast features surprise guest interviews with several doctors who were mentored by Dr. Brahmer.
Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Seminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC

Seminal Trials: Nivolumab Phase I Trial & Immunotherapy for NSCLC

IASLC